Shares in Oxford Nanopore surged as the FTSE 250 gene-sequencing specialist reported stronger than expected sales for the first half of 2025. The company expects to post revenues of around
Shares in Oxford Nanopore surged as the FTSE 250 gene-sequencing specialist reported stronger than expected sales for the first half of 2025. The company expects to post revenues of around






